Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Healey ALS MyMatch Protocole de Dépistage Commun (MCSP)

9 novembre 2026 mis à jour par: Suma Babu, Massachusetts General Hospital

Protocole commun de dépistage (MCSP) Healey ALS MyMatch pour déterminer l'éligibilité préliminaire aux essais cliniques de phase précoce ALS MyMatch

The Healey ALS MyMatch Common Screening Protocol (MCSP) is an observational study. The main goal of the study is to help connect adults living with ALS to Healey ALS MyMatch interventional clinical trials that may be a good fit for them.

People who complete an MCSP Screening Visit will undergo:

  • clinical assessments
  • laboratory testing
  • biomarker analyses

The above will be used to determine preliminary eligibility for enrolling ALS MyMatch trials. In addition to helping connect people to a Healey ALS MyMatch interventional clinical trial, the information will also be used to characterize clinical, genetic, and biofluid biomarker profiles. These profiles will help to match the right people to the right trials and evaluate the frequency of ALS-associated gene variants. Blood samples and DNA will also be stored for future ALS and biomarker research.

Aperçu de l'étude

Description détaillée

The MyMatch Common Screening Protocol (MCSP) is an observational study that is part of the Healey ALS MyMatch program. Healey ALS MyMatch is an early phase (Phase 1b or 2a), Amyotrophic Lateral Sclerosis (ALS) clinical trial program. ALS MyMatch is designed to help match adults living with ALS to Healey ALS MyMatch interventional clinical trials that may be a good fit for them.

The first step in participating in Healey ALS MyMatch is to complete a screening visit for the MCSP. MCSP screening visit activities can be completed over a period of 45-days and some screening visit activities can be completed remotely. MCSP screening visit activities include:

  • obtaining informed consent
  • reviewing medical history
  • collecting blood samples
  • completing a 12-lead ECG
  • completing questionnaires

To be eligible to participate in the MCSP, the following key criteria will need to be met: ALS diagnosis, SVC breathing score of equal to or greater than 65%, and ALS genetic testing.

The information collected at the MCSP screening visit helps researchers determine whether a participant might qualify for one or more treatment studies that are currently enrolling in the ALS MyMatch program. If a participant appears eligible for more than one study, then the participant may choose to consult with their doctor and decide which study would be a better fit for them.

Type d'étude

Observationnel

Inscription (Estimé)

500

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Healey ALS MyMatch Clinical Operations Team
  • Numéro de téléphone: 857-282-9210
  • E-mail: mghalsmymatch@mgb.org

Lieux d'étude

    • Florida
      • Davie, Florida, États-Unis, 33314
        • Pas encore de recrutement
        • Nova Southeastern University
        • Contact:
    • Illinois
    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02114
        • Recrutement
        • Massachusetts General Hospital
        • Contact:
    • Minnesota
      • Minneapolis, Minnesota, États-Unis, 55414
        • Pas encore de recrutement
        • University of Minnesota
        • Contact:
          • Tori Schirrick
          • Numéro de téléphone: (612) 626-7300
          • E-mail: kaste125@umn.edu
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

The target populations for MCSP and ALS MyMatch trials will initially focus on subgroups of individuals with ALS, including those with early-stage disease. Some ALS MyMatch trials will further target those with specific biomarkers or genetic markers for inclusion in a specific trial.

La description

Inclusion Criteria:

  1. Ability to provide written informed consent.
  2. Adults > 18 years of age.
  3. Diagnosis of symptomatic ALS that meets either the revised El Escorial Criteria.(clinically possible, probable, probable lab-supported, or definite) or the Gold Coast Criteria.
  4. Available or pending clinically obtained CLIA ALS genetic panel report.
  5. Time since onset of weakness due to ALS ≤ 24 months at the time of MCSP screening.
  6. Slow VC ≥ 65% of predicted capacity value for gender, height and age at screening.
  7. Clinically unremarkable Complete Blood Counts as per SI's discretion, including but not limited to Hemoglobin ≥ 9 g/dL.
  8. Ability and willingness to complete all study procedures per SI's assessment.
  9. Negative pregnancy test at screening for women of child-bearing potential (WOCB), defined as a sexually mature woman who has not undergone a hysterectomy or who has not been naturally postmenopausal for at least 24 consecutive months (i.e., who has had menses any time in the preceding 24 consecutive months).

Exclusion Criteria:

  1. Clinically significant unstable medical or surgical condition that would pose a risk to the participant's trial procedural participation or interfere with data collection, per SI's assessment.

  2. Presence of cognitive or mental health disorders impairing ability to provide informed consent for the study per SI assessment.

  3. Active cancer or history of cancer, unless it was successfully treated for durable remission or cure more than 3 years ago. (Note that basal cell carcinoma, squamous cell carcinoma in situ, cervical carcinoma in situ, prostatic carcinoma in situ, or other malignancies that have been curatively excised at any time previously and with no evidence of disease recurrence for at least 3 years are not exclusionary.)

  4. Prior solid organ transplantation.

  5. Use of investigational treatments for ALS (off-label use or active participation in a clinical trial) within 5 half-lives (if known) or 30 days (whichever is longer) prior to the MCSP Screening Visit. (Please refer to the Manual of Procedures (MOP) for current list of experimental therapies)

  6. Screening 12-lead ECG showing QT interval corrected for rate (QTcF) > 470 msec for women and > 450 msec for men, absence of second degree or higher AV block or other clinically significant cardiac arrythmias.

  7. Clinically significant abnormalities in the Comprehensive Metabolic Panel per SI's assessment, including but not limited to:

    1. Serum alanine aminotransferase or aspartate aminotransferase > 3 times the upper limit of normal, or serum bilirubin > 1.5 × upper limit of normal
    2. Estimated GFR (eGFR) of < 30 mL/min/1.73m2
  8. Other clinically significant electrolyte and metabolic abnormalities

  9. If female, breastfeeding, pregnant, or of child-bearing potential and unwilling to use effective contraception for duration of the trial and after discontinuing treatment as outlined in the ALS MyMatch trial protocol.

  10. Clinically significant unstable medical conditions (other than ALS) that would pose a risk to the participant, per SI's assessment (e.g., cardiovascular instability, systemic infection,), or clinically significant laboratory abnormality or ECG changes.

  11. Exposure at any time to any gene therapies under investigation for the treatment of ALS (off-label use or investigational).

  12. Participants who require Permanent assisted ventilation (PAV). PAV defined as more than 22 hours per day of noninvasive or invasive mechanical ventilation for more than seven consecutive days. The date of onset of PAV is the first day of the seven days.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: COHORT
  • Perspectives temporelles: PROSPECTIVE

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Preliminary eligibility to be matched to a MyMatch Trial
Délai: From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial.

To determine preliminary eligibility of early ALS (< 24 months from weakness onset) participants for actively enrolling ALS MyMatch trial(s)

From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Repository for future research
Délai: From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. Samples will be banked indefinitely for future research on ALS and related diseases.

To build an ALS biofluid, genetic and data repository for future clinical and translational research.

From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. Samples will be banked indefinitely for future research on ALS and related diseases.
Prevalence of gene mutations
Délai: From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. Samples will be banked indefinitely for future research on ALS and related diseases.

To characterize the prevalence of participants with causative or risk modifier gene mutations in the MCSP

From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. Samples will be banked indefinitely for future research on ALS and related diseases.
Collect and bank samples
Délai: From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. Samples will be banked indefinitely for future research on ALS and related diseases.

To collect and bank blood samples for future biofluid biomarker analyses

From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. Samples will be banked indefinitely for future research on ALS and related diseases.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

31 août 2026

Achèvement primaire (Estimé)

16 mars 2029

Achèvement de l'étude (Estimé)

16 mars 2029

Dates d'inscription aux études

Première soumission

29 janvier 2026

Première soumission répondant aux critères de contrôle qualité

6 février 2026

Première publication (Réel)

10 février 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

12 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

9 novembre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner